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Abstract
Introduction: Patients with rheumatoid arthritis (RA) have an increased risk of infection and this risk appears to be
higher with anti-TNF (tumor necrosis factor) agents. We pooled data from the cumulative abatacept RA clinical
development program, both double-blind and open-label periods, to estimate the incidence rates (IRs) of infections
requiring hospitalization including pneumonia and opportunistic infections, in comparison with RA patients treated
with non-biologic disease-modifying antirheumatic drugs (DMARDs) from several reference cohorts.
Methods: Infections reported in seven abatacept clinical trials of RA patients (double-blind and open-label periods)
were tabulated. Comparisons were made between the observed IRs in abatacept-treated patients and those in
over 133,000 patients exposed to non-biologic DMARDs in six reference RA cohorts. Age- and sex-adjusted IRs of
infections requiring hospitalization, including pneumonia (most frequent hospital infection), were used to estimate
the expected IRs with abatacept by the method of indirect adjustment. Standardized incidence ratios (SIR) and
95% CI were calculated comparing incidence in the cumulative abatacept experience with incidence in each RA
cohort.
Results: A total of 1,955 (double-blind period) and 4,134 (double-blind + open-label periods with a cumulative
exposure of 8,392 person-years) abatacept-treated RA patients were analyzed. Observed IRs for infections requiring
hospitalization during the double-blind period were 3.05 per 100-patient years for abatacept-treated patients and
2.15 per 100 patient years for placebo. In the cumulative population, observed IR for infections requiring
hospitalization was 2.72 per 100-patient years. Rates for abatacept were similar to expected IRs based on other RA
non-biologic DMARD cohorts.
Conclusions: IRs of infections requiring hospitalization and pneumonia in abatacept trials are consistent with
expected IRs based on reference RA DMARD cohorts. RA patients are at higher risk of infection compared with the
general population, making the RA DMARD cohorts an appropriate reference group. The safety of abatacept,
including incidence of infections requiring hospitalization, will continue to be monitored in a post-marketing
surveillance program.
Introduction
Patients with rheumatoid arthritis (RA) have been
shown to have an increased risk of infection compared
with the general population [1,2]. Some studies have
also shown that this risk varies according to treatment
of RA patients, with a higher risk of infections with
anti-TNF (tumor necrosis factor) agents compared with
non-biologic disease-modifying antirheumatic drug
(DMARDs) [3,4]. Treatment with biologic agents is gen-
erally a highly effective approach for patients with RA,
but may compromise host defense mechanisms involved
in protection from infections and tumor surveillance;
adverse events, serious infections in particular, are
therefore a concern [4].
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any medium, provided the original work is properly cited.Abatacept is the first in a class of agents for the treat-
ment of rheumatoid arthritis (RA) that selectively modu-
lates the CD80/CD86:CD28 co-stimulatory signal
required for T-cell activation [5]. Abatacept has demon-
strated efficacy in the treatment of rheumatoid arthritis
(RA) [6-11]. While the safety and tolerability of abata-
cept has been described in the individual randomized
trials [12], it is prudent to evaluate the overall risk of
infections requiring hospitalization (hospitalized infec-
tions), of hospitalized pneumonia, and of tuberculosis
(TB) and other opportunistic infections in the cumula-
tive trial experience.
To date, aggregate double-blind infection rates (ser-
ious and those requiring hospitalization) following aba-
tacept treatment have been published in abstract form
only and limited data have been published on the
longer-term cumulative incidence from the integrated
(double-blind and open-label) data of all abatacept
exposed patients [13,14]. Overall, a serious infection is
an infection that results in death, requires or prolongs a
hospitalization, is life-threatening or deemed as medi-
cally important by the trial investigator. Serious infec-
tion incidence rates from the integrated randomized
double-blind, placebo-controlled trials (RCTs) of abata-
cept [6-11] were 3.47/100 patient-years (py) and 2.41/
100 py for abatacept and placebo, respectively [13].
Similarly, the incidence rates of infections requiring hos-
pitalization (a subset of serious infections) in the com-
bined double-blind placebo-controlled trials was 3.05/
100 py and 2.16/100 py for abatacept and placebo,
respectively [14].
In this paper, we report on infections requiring hospi-
talizations in the cumulative experience with abatacept
from RCTs, including both the double-blind and the
open-label phases. Since no control groups are available
for the open-label extension phases, we have used exter-
nal RA cohorts to serve as comparator groups so that
the rates observed with abatacept are placed into con-
text with comparable, real-world RA populations treated
with DMARDs. This permitted the evaluation of infec-
tion risk over longer periods than the shorter follow-up
of RCTs, and allowed us to combine the experience
from multiple trials.
Materials and methods
All person-time from all patients exposed to abatacept
in the clinical development program (CDP) were
included for the computation of infections requiring
hospitalization (hospitalized infections), pneumonia
requiring hospitalization (hospitalized pneumonia), and
TB incidence rates. Several large population-based regis-
tries were utilized to establish a range of reference hos-
pitalized infection incidence rates in RA patients treated
with non-biologic DMARDs. These were compared with
the incidence rates of infections that lead to hospitaliza-
tion in abatacept-treated patients. The method of indir-
ect comparison was applied. Data reflect all patients in
clinical trials treated with abatacept through December
2006. Expected events in the RA cohorts are adjusted
for age and gender and account for exposure.
Study design
This was both a comprehensive pooled analysis of trial
data, and an observational epidemiological study exam-
ining hospitalized infections, hospitalized pneumonia,
and infections of interest (specifically TB), based on the
comparison between the occurrence of infections requir-
ing hospitalization in all patients ever exposed to abata-
cept in the CDP with the occurrence of these infections
requiring hospitalization in six observational cohorts of
RA patients in Europe and North America. Data reflect
all patients in the abatacept CDP, including double-
blind (DB) and open-label (OL) phases of RCTs,
through December 2006.
Data sources
Clinical safety data from seven abatacept RA clinical trials
were included in the analyses [6-11,15,16]. Table 1 presents
these studies. Exclusion criteria and TB screening were
consistent across all trials except for abatacept researched
in rheumatoid arthritis patients with an inadequate anti-
TNF response to validate effectiveness (ARRIVE) where
there were 23 patients who were purified protein derivative
(PPD) positive. Exclusions for TB and serious infections
included active TB requiring treatment within the previous
three years, PPD-positive subjects who had not received
adequate chemoprophylaxis or prior Bacillus Calmette-
Guerin (BCG) immunization, and subjects with any serious
bacterial infection (such as pneumonia, renal infection, or
sinusitis), unless treated and resolved with antibiotics, or
chronic bacterial infection (such as pyelonephritis and
chest infection with bronchiectasis) in the previous three
months. Of note, protocol IM101-031 enrolled RA patients
with comorbid conditions including diabetes and chronic
obstructive pulmonary disorder (COPD).
The observational RA comparison groups used to per-
form the indirect comparison analyses were derived
from the following: the British Columbia (BC) popula-
tion-based RA Cohort in Canada, the Norfolk Arthritis
Register (NOAR) in the UK, the National Data Bank for
Rheumatic Diseases (NDB) in the USA, the Early Rheu-
matoid Arthritis Register and the Swedish Inpatient
Hospitalization in Sweden (Sweden ERA, Sweden
INPT), and the PharMetrics database in the US. Charac-
teristics of these data sources have been previously
described in the literature [2,17-20]. The six observa-
tional cohorts were selected for their ability to provide
the patient population of interest (RA patients receiving
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dence rates (IRs) of the specified outcomes, and the
ability of the investigators to complete the analyses for
regulatory filings. Table 2 presents the characteristics of
these databases with respect to cohort characteristics
(type and number of patients), time period covered, and
data availability.
The PharMetrics analyses were conducted on data held
by the sponsor of the current study, while the data sources
used for the other cohort analyses are proprietary and
reside with the affiliated university or research center.
For this study, each registry and data source holder
obtained ethics or Institutional Review Board (IRB)
approval in accordance with local requirements.
Approvals are maintained and updated regularly as
required by local law for each individual study.
Exposure
The cumulative integrated abatacept experience
included 4,134 abatacept-treated patients representing
8,392 person-years of abatacept exposure from seven
clinical trials (Table 1). Because 80% of subjects in the
Table 1 Description of the abatacept clinical trials included in the current analysis
Study
name
Study design/study title/DB enrollment period Duration of double-
blind period (months)
abatacept PBO Open-label
extension
IM101101
[6] Phase IIB
Randomized, placebo-controlled, double-blind/2001 to 2002 12 85 36 80
IM101100
[7,8] Phase
IIB
Randomized, dose-ranging, placebo-controlled, double-blind/2001 to
2002
12 220 119 219
ATTAIN [9]
IM101029
Phase III
Randomized, placebo-controlled, double-blind/Abatacept Trial in
Treatment of Anti-TNF INadequate responders/2002 to 2003
6 258 133 317
AIM [10]
IM101102
Phase III
Randomized, placebo controlled, double-blind/Abatacept in
Inadequate responders to MTX/2002 to 2003
12 433 219 539
ASSURE [11]
IM101031
Phase III
Randomized, placebo-controlled, double-blind/Abatacept Study of
Safety in Use with other RA therapies/2002 to 2003
12 959 482 1184
Total double-blind 5 core above 1955 989 2689**
ATTEST [15]
IM101043
Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy
and Safety in Treating RA/2005 to 2006
12 156 110 236*
(132 aba, 104
placebo, 136
infliximab)
ARRIVE [16]
IM101064
Abatacept Researched in Rheumatoid arthritis patients with an
Inadequate anti-TNF response to Validate Effectiveness/2005 to 2006
6 (open-label) 1046 530
*IM101043, without infliximab arm; **Number represents total number of abatacept exposed patients exposed during both double-blind and open-label; five
core trials N = 2,689, overall N = 4,134.
Table 2 Characteristics of RA data sources used for epidemiologic analysis.
Data source BC PharMetrics NOAR NDB Swedish ERA Swedish
inpatient*
Country Canada United States United
Kingdom
United States Sweden Sweden
Data type Administrative data on
physician visits,
hospitalizations and
medications
Administrative
Claims data
Patient
Questionnaire &
assessment
Patient Questionnaire Electronic medical
records, patient
assessment
Medical
Records
Time covered 1996 to 2002 1998 to 2002 1990 to 1999 1998 to 2003 1994 to 2003 1990 to 2003
Number of RA
patients in
cohort
12,337 24,530 523 10,499 3,703 53,067
DMARD users Prevalent users Prevalent users Incident users Prevalent users Incident users Prevalent
users
Outcome
(infection)
ascertainment
ICD-9 codes on claims and
discharge summaries
ICD-9 codes
on claims
ICD-9 codes in
linked medical
records
Patient-reported and
verified by medical and
hospital records
ICD-10 codes and
verified by linking to
hospital registry
ICD-10 codes
in hospital
registry
*The Sweden inpatient cohort is not a DMARD-only group and may contain patients on biologic therapy.
Characteristics of data sources used for identification of RA patients included in the epidemiologic analysis. BC: British Columbia RA Cohort; NOAR: Norfolk
Arthritis Register; NDB: National Data Bank for Rheumatic Diseases; Sweden ERA: Sweden Early Rheumatoid Arthritis Register.
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DMARD therapy during the trials (most frequently
methotrexate), and almost all had prior exposure to
non-biologic DMARDs, the most relevant reference
group for comparison was considered to be non-biologic
DMARD-treated patients because they would be similar
to the placebo patients. Therefore, non-biologic
DMARD patients were retrospectively identified from
each observational data source and became part of the
study cohort. Patients with a known exposure to a
biologic agent were excluded from these observational
database cohorts. In total, approximately 137,000 non-
biologic DMARD-treated patients with RA from the
observational cohorts were identified and included in
the analyses.
Study subjects
Patients included all those who were ever exposed to
abatacept treatment anytime during the DB and OL per-
iods of the cumulative abatacept CDP (Table 3). Sub-
jects who agreed to enter the OL period after
completing the DB period were enrolled; no specific
response criteria or additional screening was required
(Table 1).
The RA DMARD cohorts examined in this study were
multinational, had varying durations of follow up, and
used different case ascertainment methods (Table 2).
Data sources consisted of claims, questionnaires and
assessments, collected over a period spanning 14 years,
between 1990 and 2003. The cohort populations varied
from around 500 patients to over 53,000. Women con-
stituted more than two-thirds of each cohort.
Across all cohorts, most patients (63% to 72%) were
between 45 and 74 years of age. While older age groups
were underrepresented in the abatacept CDP, compari-
sons of infections requiring hospitalization rates were
adjusted for age. Duration of RA was not available for
the PharMetrics and Swedish inpatient cohorts. The
duration of RA for the abatacept patients was most
similar to the BC and NDB cohorts; whereas the early
RA cohorts followed patients from disease onset. These
cohorts represent a range in RA disease duration.
Mean patient-years of follow-up per subject across RA
DMARD cohorts ranged from 2.2 to 7.9 py. Across all
cohorts in which RA medication use data were collected,
in addition to non-biologic DMARDs, use of glucocorti-
coids ranged from 37% (NOAR) to 66% (BC), while use
of non-steroidal anti-inflammatory drugs (NSAIDs) ran-
ged from 65% (NDB) to 89% (BC). The demographic
characteristics of the RA patients are presented by
cohort in Table 3.
Outcome (infection) ascertainment
Pre-specified outcomes included overall infections
requiring hospitalization pneumonia requiring hospitali-
zation (the most frequently reported infection requiring
hospitalization) and TB. Infections in this study were
identified by international classification of diseases
(ICD) -9 and ICD-10 diagnostic codes in the BC,
NOAR, PharMetrics, Swedish Inpatient, and the Sweden
ERA cohorts. Specifically, in the BC and PharMetrics
cohorts, hospitalized infections were identified from the
ICD-9 diagnostic codes recorded on discharge summa-
ries of hospitalization data. For the NOAR, hospitalized
Table 3 Baseline demographics and clinical characteristics of abatacept clinical trial patients and RA DMARD cohorts
Abatacept CDP
(N = 4,134)
BC
(N = 12,337)
NDB
(N = 10,499)
PharMetrics
(N = 52,444)
NOAR
(N = 523)
Sweden ERA
(N = 3,703)
Sweden Inpatient
(N = 53,067)
Age, n (%)
18 to 44 1,015 (25) 3,088 (25) 1,442 (14) 15,733 (30) 109 (21) 782 (21) 4,776 (9)
45 to 74 2,988 (72) 7,840 (64) 7,586 (73) 35,137 (67) 366 (70) 2,421 (66) 29,718 (56)
≥ 75 131 (3) 1,409 (11) 1,438 (14) 1573 (3) 48 (9) 500 (14) 18,573 (35)
Female, n (%) 3,323 (80) 8,936 (72) 7,971 (76) 18,569 (76) 357 (68) 2,589 (70) 37,678 (71)
Duration of RA, n (%)
<5 years 1,353 (33) 4,890 (40) 2,726 (29)* NA 523 3,703 NA
5 to 10 years 1,192 (29) 4,206 (34) 1,902 (20)* NA 0 0 NA
>10 years 1,586 (38) 3,241 (26) 4,716 (50)* NA 0 0 NA
Concomitant medications, n (%)
†
Oral corticosteroids 2,657 (64) 8,121 (66) 4,588 (44) 11,504 (48) 194 (37) NA NA
NSAIDS 3,113 (75) 11,001(89) 6,820 (65) NA 416 (80) NA NA
Total follow-up (years)
Mean 2.1 4.9 3.3 2.2 7.9 3.6 5.6
Median 1.8 6.0 2.5 2.0 9.3 NA NA
*RA duration was not collected for every subject in the NDB; therefore, n = 9,344 for this variable.
†Use of concomitant medications at baseline is presented for
the abatacept trial population, whereas, use during follow-up is presented for the RA cohorts (where available). BC, British Columbia population-based RA Cohort;
NDB, National Data Bank for Rheumatic Diseases; NOAR, Norfolk Arthritis Register; Sweden ERA, Sweden Early Rheumatoid Arthritis Register. NA = not available.
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cohort with the electronic records system of the region’s
only major hospital. In the Sweden ERA cohort, infor-
mation on hospitalized infections was acquired through
linkage to the inpatient hospitalized discharge diagnosis
and hospital discharge diagnoses were used for the
Swedish Inpatient data source records. In the NDB, hos-
pitalized infections were identified from semi-annual
questionnaires sent to participants. All reports of hospi-
talized infections were validated with hospital and medi-
cal records. For patients in the abatacept CDP,
hospitalized infections were identified from all adverse
event (AE) reports and validated through special event
forms; events were included regardless of relationship to
study drug.
Analyses
Baseline demographic and clinical characteristics were
summarized using descriptive statistics for continuous or
categorical variables as appropriate. In the abatacept
CDP, all episodes of hospitalized infections, hospitalized
pneumonia and TB cases were counted from the start of
therapy until the first event or end of treatment period +
56 days, whichever occurred first.
Rates were computed for the double-blind period, as
well as the cumulative (double blind and open label)
study period. In the RA DMARD observational cohorts,
person-time and incidence of hospitalized infections,
hospitalized pneumonia and TB were calculated from
the first recorded non-biologic DMARD exposure until
the first event or the end of follow-up, whichever
occurred first. The IRs for each outcome of interest in
the RA DMARD cohorts were standardized to the age
(10-year interval) and sex distribution of the abatacept
clinical trial experience by the method of indirect stan-
dardization. All cases of TB are reported. TB rates were
not standardized due to the insufficient number of cases
therefore overall rates from each data source are pre-
sented. For all outcomes, an indirect comparison was
computed using the number of events observed in the
abatacept CDP and the number of events expected
given the same age, sex, and exposure distribution in
the RA cohorts.
To estimate the relative risk (RR) of hospitalized infec-
tions and pneumonia in the abatacept CDP relative to
that in each of the six RA DMARD cohorts, standardized
incidence ratios (SIRs) were calculated by an indirect
comparison method of dividing the observed numbers of
infections in the abatacept CDP by the expected numbers
from the RA DMARD cohorts. The expected numbers
were calculated by multiplying the hospitalized infection
rates in each of the six RA cohorts by the observed per-
son-years at risk, stratified by sex and the 10-year age
group. Rate ratios calculated between groups based on
incidence rates of events was calculated by the method of
DerSimonian and Laird [21]. Furthermore, we computed
a summary SIR estimate (and 95% CI) combining the
SIRs from the six DMARD cohorts based on the meta-
analysis method of DerSimonian and Laird [21]. This
method uses a random effects model which considers
both within-study and between-study variation by
incorporating the heterogeneity of effects in the overall
analysis. For all SIRs, 95% CI was calculated using the
Wilson and Hilferty approximation [22]. Statistical ana-
lyses were performed using the SAS software package
(SAS Institute, Cary, North Carolina, USA). Crude inci-
dence rates from the RA DMARD cohorts were reported
for TB and compared with the crude incidence rate in
the abatacept CDP.
Results
The cumulative integrated abatacept experience
included 4,134 abatacept-treated patients representing
8,392 person-years of abatacept exposure from seven
clinical trials (Table 1). Because 80% of subjects in the
abatacept CDP were on background non-biologic
DMARD therapy during the trials (most frequently
methotrexate), and almost all had prior exposure to
non-biologic DMARDs, the most relevant reference
group for comparison was considered to be non-biologic
DMARD-treated patients because they would be similar
to the placebo patients
Presented in Table 4 are the total number of events as
well as the incidence rates for infections requiring hos-
pitalization (hospitalized infections) and pneumonia
requiring hospitalization (hospitalized pneumonia) in
the cumulative abatacept CDP (observed) and RA
cohorts (expected). The incidence rate for hospitalized
infections in the DB periods of the RCTs was 3.05/100
py for abatacept and 2.15/100 py for placebo (rate ratio
1.42; 95% CI: 0.82 to 2.45).
For hospitalized pneumonia, the incidence rate in the
DB periods of RCTs was 0.71/100 py for abatacept and
0.50/100 py for placebo (Table 4). The incidence rate in
the cumulative abatacept population for hospitalized
infections was 2.72/100 py, which falls within the range
of expected values calculated for the external cohorts
(1.41 to 3.92/100 py) (Table 4). The incidence rate in
the cumulative abatacept population for hospitalized
pneumonia was 0.65/100 py, which also falls within the
range of incidence rate values calculated for the external
cohorts (0.27 to 1.31/100 py).
T h eo v e r a l li n c i d e n c er a t eo fT Bi nt h ec u m u l a t i v e
abatacept clinical trial experience was low and compar-
able with the RA cohorts (Table 5). Three cases of TB
were reported for a cumulative rate of 0.04/100 py.
There was no increased incidence of TB compared with
the RA cohorts.
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the abatacept CDP. Other opportunistic infections
reported included one event each of aspergillosis, blasto-
mycosis, and systemic Candida infection reported. No
events resulted in hospitalization. No cases of coccidioi-
domycosis, cryptococcus, histoplasmosis, nocardiosis, or
Pneumocystis carinii pneumonia were observed.
Standardized incidence ratios (SIRs) of hospitalized
infections and pneumonia are listed according to data
source (Figure 1A and 1B, respectively). These SIRs
represent the risk of infections requiring hospitalization
in the cumulative abatacept experience compared with
each of the RA cohorts. Using the DerSimonian and
Laird [21] method, a pooled SIR for hospitalized infec-
tions and hospitalized pneumonia were calculated. The
pooled SIR for hospitalized infection was 1.16 (95% CI
0.79 to 1.70) and 0.94 (95% CI 0.58 to 1.53) for hospita-
lized pneumonia.
Discussion
As placebo is the best comparator but is generally lim-
ited to use within the double-blind phase of an RCT,
this study provides context for infections requiring hos-
pitalization in patients with an inadequate response to
methotrexate or an anti-TNF agent who were treated
with long-term exposure to abatacept in the clinical
development program.
Bongartz and Saillot has shown an increase in serious
infections in the double-blind phase of biologic studies
when compared to placebo [3,23]. Previously stated,
results from the double-blind randomized trials suggest
an increase in serious infections: 3.47/100 patient-years
(py) and 2.41/100 py for abatacept and placebo, respec-
tively [13] (rate ratio 1.44 (0.86 to 2.42)). This serious
infection rate ratio of 1.44 (0.86 to 2.42) is within the
lower limit of the 95% CI for the pooled odds ratio
reported in the meta-analysis of serious infections in
Table 4 Observed and expected IRs of hospitalized infections, and pneumonia, in abatacept CDP and RA cohorts.
Data source Counts Hospitalized infections*
IR**/100 py (95% CI)
Counts Hospitalized pneumonia*
IR**/100 py (95% CI)
Observed (Double-blind trial data)
Abatacept Population
N = 1,955
51 3.05
(2.3, 4.0)
12 0.71
(0.4, 1.3)
Placebo Population
N = 989
17 2.15
(1.26, 3.45)
4 0.50
(0.14, 1.29)
Observed (Long-term open-label trial data)
Cumulative Abatacept Trial Population (DB + OL)
N = 4,134
221 2.72
(2.37,3.10)
54 0.65
(0.47, 0.82)
Expected (Observational cohort data)
BC 252 3.00
(2.65, 3.40)
66 0.79
(0.62, 1.01)
NDB NA NA 110 1.31
(1.09, 1.58)
PharMetrics 296 3.53
(3.15, 3.96)
106 1.26
(1.04, 1.53)
NOAR 118 1.41
(1.18, 1.69)
22 0.27
(0.18, 0.40)
Sweden ERA 154 1.83
(1.57, 2.15)
44 0.53
(0.39, 0.71)
Sweden INPT 329 3.92
(3.52, 4.37)
87 1.04
(0.84, 1.28)
No cases of coccidioidomycosis, cryptococcus, histoplasmosis, nocardiosis, or Pneumocystis carinii pneumonia were observed. *Rates in external RA cohorts are
age-(10-year groups) and sex-adjusted to the abatacept trial population. **Rates are cases per 100 py;
†crude, unadjusted rate. BC: British Columbia RA Cohort;
NA: not available; NOAR: Norfolk Arthritis Register; NDB: National Data Bank for Rheumatic Diseases; Sweden ERA: Sweden Early Rheumatoid Arthritis Register
Table 5 Observed overall incidence rates of tuberculosis
in the abatacept CDP and RA cohorts
Cohort Tuberculosis
IR/100 py (95% CI)
Observed IR
DB Abatacept Population 0.06 (0.0 to 5.6)
DB Placebo Population 0.13 (0.0 to 5.6)
Cumulative Abatacept Population
(DB + OL)**
0.04 (0.01 to 0.10)
Expected IR
BC 0.03 (0.01 to 0.05)
NDB 0.02 (0.01 to 0.04)
PharMetrics 0.02 (0.01 to 0.04)
NOAR 0.013*
Sweden ERA 0.026 (0.003 to 0.094)
Sweden INPT 0.05 (0.04 to 0.06)
*95% CI not available. **n = 3.
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Page 6 of 11Figure 1 Standardized incidence ratios (SIR) comparing the risk of hospitalized infections (A) and pneumonia (B) in abatacept CDP
and RA cohorts. Expected events are age-adjusted (10-year age groups) and gender-adjusted and account for exposure. Data reflect all patients
in clinical trials treated with abatacept through December 2006. Overall SIRs were derived through a meta-analysis of SIRs using individual
cohorts.
Simon et al. Arthritis Research & Therapy 2010, 12:R67
http://arthritis-research.com/content/12/2/R67
Page 7 of 11anti-TNF controlled trials by Bongartz (pooled Mantel-
Haenszel OR 2.0 (1.3 to 3.1)) [3] and similar to the
fixed combined OR of 1.35 (0.79 to 2.32) reported by
Saillot [23].
The incidence rate for hospitalized infections (a subset
of serious) in the DB periods of the RCTs was also
increased however again not significant: 3.05/100 py for
abatacept and 2.15/100 py for placebo (rate ratio 1.42;
95% CI: 0.82 to 2.45).
T h ec u m u l a t i v ed a t ap r e s e n t e dh e r es u g g e s tt h a tt h e
observed incidence rates of infections requiring hospita-
lization (hospitalized infections) hospitalized pneumonia,
and TB in patients ever treated with abatacept in the
cumulative CDP (both double-blind and open-label) is
in the same order of magnitude as those expected from
cohorts of RA patients treated with non-biologic
DMARDs.
As patients who are enrolled in RCTs move from the
double-blind to open label phases, the lack of a control
group to monitor the occurrence of adverse events in
the long term becomes challenging. It is difficult to
assess whether the risk of infection in patients with RA
is due to underlying RA, as suggested by Dobloug, Fox
and Koetz [24-26], or by the treatments administered.
Some studies have demonstrated that the use of corti-
costeroids may increase infection risk [19,27-29] as well
as anti-TNF agents given to patients with RA [30-32].
With potential confounding by disease activity, disease
severity, duration of disease, presence of comorbid con-
ditions, and concomitant treatment, it becomes challen-
ging to determine a true association between the risk of
infections and a new treatment.
To date, there have not been any similar such studies
evaluating cumulative exposure of a biologic agent to an
external cohort. There have been a number of observa-
tional studies reporting rates of infection by treatments
and there are cumulative and open-label study periods
that have been reported. However none have offered a
combined evaluation as the analysis reported here.
When conducting pharmacoepidemiologic studies, it
has been recommended that at least two cohorts be
evaluated to establish the extent of reproducibility [33].
The resulting variation in IRs among the cohorts pro-
vides a useful range of estimates for comparison, which
is preferable to a single cohort IR. Also, published litera-
ture suggests that RA patients are at higher risk of
infection compared with the general population, render-
ing the RA DMARD observational cohorts an appropri-
ate reference group and not the general population
[2,29].
There have been a number of published papers evalu-
ating the risk of infections in RA patients where the
exposure, outcomes, and risk measurement were not
consistent across studies. These definitions include, but
are not limited to, the regulatory definition of serious,
hospitalized infections, and the possible inclusion of
administration of IV antibiotics [23]. For transparency,
the authors defined the outcomes and present the
number of events, incidence rates, and percentages
(proportions) for the RA cohorts and abatacept CDP.
This study has several limitations, including those
inherent to its design. The data collected and analyzed
from the RA cohorts were not primarily collected for
this type of study. The limitations associated with the
use of external control groups include, but are not
limited to, differences in physician management and
diagnoses of RA, the inclusion of both prevalent and
new users of DMARD agents, differences in the
ascertainment and verification of outcomes, length of
follow-up, validity of RA diagnosis, disease duration, and
severity of disease. We acknowledge that these variables
may be different among the RA cohorts. Although the
abatacept population appeared to be demographically
similar to the cohorts, clinical trial patients are inher-
ently different. The abatacept CDP enrolled mainly
prevalent, stable non-biologic DMARD users who had
an inadequate response to their current therapy; thereby
implying more severe disease in these patients. The RA
cohort populations were a diverse group of both preva-
lent and new non-biologic DMARD users. It is difficult
to know how comparable the RA cohorts are to the aba-
tacept trial population.
The RA cohort populations are potentially more stable
in that for this analysis the population had to be on a
non-biologic DMARD throughout follow-up without
addition of a biologic therapy. However, the non biolo-
gic DMARD treatment in these groups could be altered
during follow-up such that non biologic DMARD ther-
apy could be increased, decreased, or another non-biolo-
gic treatment could be added to the current regimen all
together. As with any population (trial or observational),
it is difficult to know if a patient was previously exposed
to a biologic agent for RA or had any other indicated
comorbid condition (psoriasis, transplant) prior to entry
into the trial or cohort. Trial patients may be monitored
more closely for adverse events, which might overesti-
mate our calculated SIRs. However, some of the cohorts
have pre-specified observation times for patients
enrolled in the registry (for example, NOAR). TB
screening prior to entry in the trials may have resulted
in a lower incidence of TB in the abatacept CDP. The
exclusion of patients with a recent infection, suggesting
that enrolled patients are potentially healthier, may have
resulted in a lower overall incidence of infections, how-
ever the authors did apply this exclusion to the data to
be more reflective of the trial population. We were not
able to adjust for potential confounders such as severity
of disease (rheumatoid factor (RF) or anticitrullinated
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morbidities, and use of non-DMARD medications (for
example, NSAIDs and corticosteroids) due to unavail-
ability of data on these variables in most external
cohorts. Finally, each of the databases used in this study
m a yb ea s s o c i a t e dw i t hs p e c i fic limitations, such as
uncertainty surrounding diagnostic accuracy in adminis-
trative claims databases (for example, BC), small cohort
size (for example, NOAR), use of self-reporting (for
example, NDB), and so on. However, these individual
limitations were minimized by the use of multiple
cohorts, resulting in a range of references that provided
relatively consistent results.
This study has several strengths. The authors prede-
fined exposure and outcome criteria in an attempt to
harmonize the methods applied to this analysis includ-
ing exposure to non-biologic DMARDs, definition of
events (hospitalized infections), and the computation of
person-time in the evaluation of infections in the abata-
cept CDP and the RA cohorts.
In randomized trials, serious infections are defined as
infection resulting in death, life threatening, requiring
inpatient hospitalization or prolongation of a hospitali-
zation, resulting in disability, a congenital anomaly or a
medically important event based on medical and scienti-
fic judgment. This definition is difficult to apply to
observational cohort data. Hence, ‘infections resulting in
hospitalization’ was used since this outcome can be
easily identified in all external observational RA data
sources.
The effort to harmonize the methods used in these
cohorts may seem trivial; however, Solomon and collea-
gues outlined the importance and complexities of defin-
ing exposure risk windows, comparators and endpoints,
and when different, the challenge in interpreting data
from epidemiological studies published independently
[34]. The analyses presented here from six RA cohorts
were done in collaboration with registry and observa-
tional data holders in an attempt to control these key
methodologic issues.
Despite geographic differences and differences in
ascertainment methods, the ranges of age- and sex-
adjusted IRs were relatively similar among the various
RA cohorts. The Early RA cohorts provided IRs on less
severe patients with shorter duration of disease where
NDB and BC have patients with longer disease duration.
Additional strengths include the choice of comparison
group. We were able to include in this study, as a refer-
ence group, only those patients treated with non-biolo-
gic DMARDs from the respective RA cohorts. Given
that non-biologic DMARDs comprised the background
therapy in all abatacept-treated patients in the clinical
trials, this constituted an appropriate reference group
for comparing risk of infections.
There have been few opportunistic infections observed
throughout the abatacept CDP. TB was the most com-
mon, with a total of three events reported in 4,134
patients over a total of 8,392 person-years, none of
which resulted in hospitalization.
Conclusions
In conclusion, the comparison of data from the cumula-
tive abatacept clinical trials and external RA cohorts
exposed to non-biologic DMARDs puts the ABA dou-
ble-blind trial populations and cumulative abatacept
experience into perspective, and suggests that in the
long-term, the risk of hospitalized infection and hospita-
lized pneumonia following abatacept treatment in these
open-label trials is in the same order of magnitude as
that of patients on non-biolo g i cD M A R Dt h e r a p y .I n c i -
dence rates and number of actual events reported in the
cumulative abatacept trial population fall within the
range of those expected based on infection rates in
external RA cohorts.
Additional file 1: Abatacept epidemiology study group members.A
Word file containing a complete list of all members of the Abatacept
Epidemiology Study Group.
Abbreviations
ACPA: anticitrullinated protein/peptide antibody; AE: adverse event; BC:
British Columbia; BCG: Bacillus Calmette-Guerin; CDP: clinical development
program; CI: confidence interval; COPD: chronic obstructive pulmonary
disease; DB: double blind; DMARD: disease-modifying antirheumatic drug;
ICD: international classification of diseases; IR: incidence rate; IRB: institutional
review board IV: intravenous; NDB: the National Data Bank for Rheumatic
Diseases in the USA; NOAR: the Norfolk Arthritis Register in the UK; NSAID:
non-steroidal anti-inflammatory drug; OL: open label; PPD: purified protein
derivative; PY: patient years; RA: rheumatoid arthritis; RCT: randomized
controlled clinical trial; RF: rheumatoid factor; RR: relative risk; SAS: Statistical
Analysis System; SIR: standardized incidence ratio; Sweden ERA: the Early
Rheumatoid Arthritis Register in Sweden; Sweden INPT: the Swedish
Inpatient Hospitalization; TB: tuberculosis; TNF: tumor necrosis factor.
Acknowledgements
We thank John Esdaile (BC), Lars Klareskog (Sweden), and Alan Silman (UK)
for being initial and continued members of the abatacept epidemiology
study group [see Additional file 1] and contributing to the initial concepts
and overseeing the methods for this work within their organizations. We
thank Michael Corbo (Bristol-Myers Squibb) who supported this work as part
of the development program for abatacept. We thank Corine Gaillez for
helpful discussions and critical reading of the manuscript. We also thank
Sean M. Gregory for medical writing support and assistance with the
electronic submission on behalf of the authors. This study and the studies of
abatacept discussed herein, as well as medical writing support for this
manuscript, were funded by Bristol-Myers Squibb Co. No author was
remunerated for their work on this manuscript. Those authors and
contributors acknowledged for their work on this study who are full-time
employees of Bristol-Myers Squibb Co. were the only individuals involved in
the analysis of data and development of this manuscript. The greater
funding body did not play a role in the analysis of data or development or
approval of this manuscript.
Author details
1Global Health Economics and Outcomes Research, Bristol-Myers Squibb,
Route 206 and Province Line Roads, Lawrenceville, NJ 08540, USA.
Simon et al. Arthritis Research & Therapy 2010, 12:R67
http://arthritis-research.com/content/12/2/R67
Page 9 of 112Department of Medicine, Clinical Epidemiology Unit, Karolinska University
Hospital Solna, Rheumatology Unit d2:01, Karolinska University Hospital
Solna, 171 76 Stockholm, Sweden.
3Division of Rheumatology, Department
of Medicine, Arthritis Research Centre of Canada, University of British
Columbia, 895 West 10th Ave., Vancouver, BC V5Z 1L7, Canada.
4Arc
Epidemiology Unit, School of Medicine, University of Manchester, Stopford
Building, Oxford Road, Manchester, M13 9PT, UK.
5Current address: Medical
School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK.
6Department of Internal Medicine, National Data Bank for Rheumatic
Diseases, Arthritis Research Foundation and University of Kansas, 1035 N.
Emporia, Suite 288, Wichita, KS 67214, USA.
7Global Biostatistics, 311
Pennington Rocky Hill Road, Bristol-Myers Squibb, Hopewell, NJ 08525, USA.
8Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish
General Hospital, 3755 Cote Ste-Catherine, Montreal, Québec H3T 1E2,
Canada.
9Departments of Medicine and Epidemiology and Preventive
Medicine, University of Maryland School of Medicine, 10 S. Pine St., MSTF 8-
34, Baltimore, MD 21201, USA.
Authors’ contributions
TS conceived the study, participated in the data analyses, and prepared and
revised the manuscript. JA provided data from the Swedish ERA and
Inpatient cohorts, reviewed and revised the manuscript. DL provided data
from the BC Cohort reviewed and revised the manuscript. JF provided data
from the NOAR cohort reviewed and revised the manuscript. FW provided
data from the NDB reviewed and revised the manuscript. AC reviewed and
validated all computations used in the statistical analyses. SS contributed to
the PharMetrics analyses, performed the SIR meta-analyses, reviewed and
revised the manuscript. MH contributed to the PharMetrics analyses,
provided medical input reviewed and revised the manuscript. All authors
read and approved the final manuscript. Authors were not paid for their
contribution to this manuscript. Their institutions did receive a grant funded
by BMS to perform the analyses.
Competing interests
TS and AC are current full-time employees of Bristol-Myers Squibb. JA
reports having been an invited speaker at meetings sponsored by Schering-
Plough and Abbott. JF reports having received research funding from
Bristol-Myers Squibb. DL reports receiving research funding from Bristol-
Myers Squibb for the research presented in this manuscript and has
participated in advisory meetings supported by Bristol-Myers Squibb. FW
reports having received research grants from Bristol-Myers Squibb, Centocor,
Abbott, Amgen and UCB. SS reports having served as an advisor and
participating as a speaker in scientific meetings for AstraZeneca, Boehringer
Ingelheim, GlaxoSmithKline, Pfizer, and Sepracor. SS also reports receiving
research funding from AstraZeneca and GlaxoSmithKline. MH reports serving
as a consultant to Amgen, Bristol-Myers Squibb, Abbott, UCB and Roche.
Received: 22 October 2009 Revised: 4 March 2010
Accepted: 14 April 2010 Published: 14 April 2010
References
1. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE: Frequency of
infection in patients with rheumatoid arthritis compared with controls: a
population-based study. Arthritis Rheum 2002, 46:2287-2293.
2. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA:
The risk of hospitalized infection in patients with rheumatoid arthritis. J
Rheumatol 2008, 35:387-393.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-
TNF antibody therapy in rheumatoid arthritis and the risk of serious
infections and malignancies: systematic review and meta-analysis of rare
harmful effects in randomized controlled trials. JAMA 2006,
295:2275-2285.
4. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ: Serious
infection following anti-tumor necrosis factor alpha therapy in patients
with rheumatoid arthritis: lessons from interpreting data from
observational studies. Arthritis Rheum 2007, 56:2896-2904.
5. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J,
Ledbetter JA, Linsley PS: Induction of alloantigen-specific
hyporesponsiveness in human T lymphocytes by blocking interaction of
CD28 with its natural ligand B7/BB1. J Exp Med 1993, 177:165-173.
6. Moreland LW, Alten R, Bosch Van den F, Appelboom T, Leon M, Emery P,
Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC: Costimulatory
blockade in patients with rheumatoid arthritis: a pilot, dose-finding,
double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and
LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002,
46:1470-1479.
7. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S,
Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC,
Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis by selective
inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med
2003, 349:1907-1915.
8. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S,
Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW: Treatment of
rheumatoid arthritis with the selective costimulation modulator
abatacept: twelve-month results of a phase iib, double-blind,
randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:2263-2271.
9. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C,
Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M:
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor
alpha inhibition. N Engl J Med 2005, 353:1114-1123.
10. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-
Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R: Effects of
abatacept in patients with methotrexate-resistant active rheumatoid
arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
11. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E: Safety
of the selective costimulation modulator abatacept in rheumatoid
arthritis patients receiving background biologic and nonbiologic
disease-modifying antirheumatic drugs: A one-year randomized,
placebo-controlled study. Arthritis Rheum 2006, 54:2807-2816.
12. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T,
Schmidely N, Le Bars M, Dougados M: Efficacy and safety of the selective
co-stimulation modulator abatacept following 2 years of treatment in
patients with rheumatoid arthritis and an inadequate response to anti-
tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547-554.
13. Simon TA, Smitten AL, Meng M, Franklin J, Askling J, Lacaille D, Wolfe F,
Suissa S, Hochberg M: Observed and expected hospitalized infections in
the abatacept clinical development program: An updated
epidemiological assessment. American College of Rheumatology, November;
Boston, Massachusetts 2007, FRI 821/849.
14. Simon TA, Covucci A, Meng M, Skovron ML: Descriptive overtime analysis
of infections and malignancies in the abatacept clinical development
program. American College of Rheumatology; November; Boston,
Massachusetts 2007, FRI 1039/1271.
15. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S,
Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M: Efficacy
and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in
patients with rheumatoid arthritis and an inadequate response to
methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
16. Schiff M, Pritchard C, Zhou X, Bahrt K, Genovese MC: The efficacy of
abatacept in patients with active rheumatoid arthritis and an
inadequate response to anti-TNF therapy: The ARRIVE trial. Arthritis
Rheum 2007, 56-S391, Abstract 942.
17. Symmons DP, Silman AJ: The Norfolk Arthritis Register (NOAR). Clin Exp
Rheumatol 2003, 21:S94-99.
18. Lacaille D, Anis AH, Guh DP, Esdaile JM: Gaps in care for rheumatoid
arthritis: a population study. Arthritis Rheum 2005, 53:241-248.
19. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R,
Feltelius N, Lindblad S, Klareskog L: Swedish registers to examine drug
safety and clinical issues in RA. Ann Rheum Dis 2006, 65:707-712.
20. Wolfe F, Caplan L, Michaud K: Treatment for rheumatoid arthritis and the
risk of hospitalization for pneumonia: associations with prednisone,
disease-modifying antirheumatic drugs, and anti-tumor necrosis factor
therapy. Arthritis Rheum 2006, 54:628-634.
21. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177-188.
22. Wilson EB, Hilferty MM: The distribution of chi-square. Proc Nat Acad Sci
1931, 17:684-688.
23. Salliot C, Dougados M, Gossec L: Risk of serious infections during
rituximab, abatacept and anakinra treatments for rheumatoid arthritis:
Simon et al. Arthritis Research & Therapy 2010, 12:R67
http://arthritis-research.com/content/12/2/R67
Page 10 of 11meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis
2009, 68:25-32.
24. Dobloug JH, Forre O, Kvien TK, Egeland T, Degre M: Natural killer (NK) cell
activity of peripheral blood, synovial fluid, and synovial tissue
lymphocytes from patients with rheumatoid arthritis and juvenile
rheumatoid arthritis. Ann Rheum Dis 1982, 41:490-494.
25. Fox RI, Fong S, Tsoukas C, Vaughan JH: Characterization of recirculating
lymphocytes in rheumatoid arthritis patients: selective deficiency of
natural killer cells in thoracic duct lymph. J Immunol 1984, 132:2883-2887.
26. Koetz K, Bryl E, Spickschen K, O’Fallon WM, Goronzy JJ, Weyand CM: Tc e l l
homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA
2000, 97:9203-9208.
27. Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients
taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
28. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE: Predictors of
infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300.
29. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM: Use of
nonbiologic disease-modifying antirheumatic drugs and risk of infection
in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:1074-1081.
30. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M,
Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, et al: Infections in patients
with rheumatoid arthritis treated with biologic agents. Arthritis Rheum
2005, 52:3403-3412.
31. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C: Drug-specific and time-
dependent risks of bacterial infection among patients with rheumatoid
arthritis who were exposed to tumor necrosis factor alpha antagonists.
Arthritis Rheum 2007, 56:4226-4227.
32. Askling J, Dixon W: The safety of anti-tumour necrosis factor therapy in
rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:138-144.
33. Food and Drug Administration. Guidance for Industry. Good
Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.
[http://www.fda.gov/cber/gdlns/pharmacovig.htm].
34. Solomon DH: The comparative safety and effectiveness of TNF-alpha
antagonists. J Manag Care Pharm 2007, 13:S7-18.
doi:10.1186/ar2984
Cite this article as: Simon et al.: Infections requiring hospitalization in
the abatacept clinical development program: an epidemiological
assessment. Arthritis Research & Therapy 2010 12:R67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Simon et al. Arthritis Research & Therapy 2010, 12:R67
http://arthritis-research.com/content/12/2/R67
Page 11 of 11